| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.025 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.9 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.019 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |